Showing results (151-160 of 183) with videos related to
Sort By:
Pageof 19
Current HIV Research|October 16, 2012
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive studyDaniel Podzamczer, Esteban Martínez, Pere Domingo, et al.Plos One|October 12, 2016
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective StudyJesús Troya, Pablo Ryan, Esteban Ribera, et al.Plos One|February 10, 2017
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective StudyJesús Troya, Pablo Ryan, Esteban Ribera, et al.The Lancet. Infectious Diseases|June 12, 2015
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trialJosé R Arribas, Pierre-Marie Girard, Roland Landman, et al.The Lancet. HIV|July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.Journal for Immunotherapy of Cancer|March 30, 2021
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 12, 2009
Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppressionDavid M Moore, Ross Harris, Viviane Lima, et al.The Lancet. HIV|June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trialsChloe Orkin, Edwin DeJesus, Paul E Sax, et al.Antiviral Therapy|September 6, 2002
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)Daniel Podzamczer, Elena Ferrer, Ezequiel Consiglio, et al.Biochemical Pharmacology|June 29, 2021
Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapyLorena Vigón, Paula Martínez-Román, Sara Rodríguez-Mora, et al.Pageof 19